Find medicine
What's new
FAQs
Latest news
Report on COVID-19 vaccine strain updates: global regulators agree on timing and data requirements
GLP-1 receptor agonists: available evidence not supporting link with suicidal and self-injurious thoughts and actions
Due to planned system maintenance, several EMA applications will be fully or partially inaccessible from 11 to 17 April.
The European Medicines Agency (EMA) reminds applicants and marketing authorisation holders that adjusted fees for all applications, except for pharmacovigilance procedures, will be coming into effect on 1 April 2024.
The European Medicines Agency's (EMA) office is closed from 18:30 on Wednesday 27 March 2024 to 07:30 on Tuesday 2 April 2024. Outside of working hours and on public holidays, it is possible to call the product emergency hotline on +31(0)88 781 7600.
EMA has issued recommendations for the influenza virus strains that vaccine manufacturers should include in vaccines for the prevention of seasonal influenza from autumn 2024.
Events
EudraVigilance is the EU's system for managing and analysing information on adverse reactions to medicines which have been authorised or are being studied in clinical trials in the European Economic Area (EEA) and supports the reporting and analysis of suspected adverse reactions originating from clinical trials and the post-authorisation phase of...
Join this information session and learn how to apply to the EMA traineeship